Recent advances in pharmacogenetic approaches to anticancer drug development

Drug Development Research

Volumn 62, Issue 3, 2004, Pages 233-253

  Smith, Nicola F ^a   Figg, William D ^a   Sparreboom, Alex ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer chemotherapy; Drug development; Pharmacogenetics

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 3A; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUTAMIDE; GEFITINIB; GLYCOPROTEIN P; IFOSFAMIDE; IMATINIB; IRINOTECAN; PACLITAXEL; TAMOXIFEN; TENIPOSIDE; THALIDOMIDE; THIOPURINE METHYLTRANSFERASE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME IMPRINTING; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INDIVIDUALIZATION; PHARMACODYNAMICS; PHARMACOGENETICS; PRESCRIPTION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 10044257623     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10361     Document Type: Review

References (160)

1. Agundez JA, Ledesma MC, Ladero JM, Benitez J. 1995. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265-269.
2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. 1996. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-146.
3. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. 1998. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5339.
4. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, and others. 2001. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217-221.
5. Amirimani B, Walker AH, Weber BL, Rebbeck TR. 1999. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91:1588-1590.
6. Ando Y, Fuse E, Figg WD. 2002a. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973.
7. Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD. 2002b. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 1:669-673.
8. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. 2000. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926.
9. Aono S, Yamada Y, Keino H, Hanada N, Nakagawa T, Sasaoka Y, Yazawa T, Sato H, Koiwai O. 1993. Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 197:1239-1244.
10. Aono S, Yamada Y, Keino H, Sasaoka Y, Nakagawa T, Onishi S, Mimura S, Koiwai O, Sato H. 1994. A new type of defect in the gene for bilirubin uridine 5′-diphosphate-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type I. Pediatr Res 35:629-632.
11. Aono S, Adachi Y, Uyama E, Yamada Y, Keino H, Nao T, Koiwai O, Sato H. 1995. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 345:958-959.
12. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, Kamataki T. 2001. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 281:1256-1260.
13. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Hondt JV, Hendrickx J, Mannens G, Bohets H, and others. 2002. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579-1589.
14. Bernal M, Arcocha J, Peralta P, Valdizan JR. 1999. [Dystonic movements: a possible secondary effect of gabapentin]. Rev Neurol 28:1215.
15. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM. 1998. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129:716-718.
16. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Onde Elferink RP, and others. 1995. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
17. Bradford LD. 2002. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243.
18. Brinkmann U, Eichelbaum M. 2001. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 1:59-64.
19. Cascorbi I, Geerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. 2001. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174.
20. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. 2003. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med 41:1345-1350.
21. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. 2003. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89-95.
22. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. 2000. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10:217-223.
23. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. 1995. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520.
24. Dai D, Tang J, Hose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. 2001a. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831.
25. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. 2001b. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607.
26. de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL. 2004. ABCG2 pharmacogenetics: ethnic differences in allele frequency, and assessment of influence on irinotecan disposition. Clin Cancer Res (in press).
27. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. 1994. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598.
28. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. 1999. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485-505.
29. Dehal SS, Kupfer D. 1997. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402-3406.
30. Desai AA, Innocenti F, Ratain MJ. 2003. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene 22:6621-6628.
31. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. 2004. J Pharmacol Exp Ther (in press).
32. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. 2001. Identification and functional characterization of a new CYP2C9 variant (CYP2C9°5) expressed among African Americans. Mol Pharmacol 60:382-387.
33. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
34. Evans WE, McLeod HL. 2003. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538-549.
35. Evans WE, Relling MV. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
36. Evans WE, Relling MV. 2004. Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468.
37. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. 1991. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985-989.
38. Ewesuedo RB, Iyer L, Das S, Koenig A, Mani S, Vogelzang NJ, Sclulsky RL, Brenckman W, Ratain MJ. 2001. Phase 1 clinical and pharmacogenetic study of TAS-103 in patients with advanced cancer. J Clin Oncol 19:2084-2090.
39. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. 2002. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 306:63-73.
40. Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G, Kimura S. 1995. Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 50:1015-1020.
41. Finnstrom N, Bjelfman C, Soderstrom TG, Smith G, Egevad L, Norlen BJ, Wolf CR, Rane A. 2001. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur J Clin Invest 31:880-886.
42. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL, Jr., Bhat K, Kim RB, Wilkinson GR. 2003. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
43. Forman BM. 2001. Polymorphisms in promiscuous PXR: an explanation for interindividnal differences in drug clearance? Pharmacogenetics 11:551-552.
44. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. 2003. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem 49:1008-1011.
45. Gelderblom H, Loos WJ, Sissung TM, Burger H, Nooter K, Soepenberg O, Nortier H, Verweij J, Figg WD, Sparreboom A. 2004. Effect of ABCG2 genotype and intestinal mRNA expression on the bioavailability of topotecan. Proc Am Soc Clin Oncol 22:130 (abstract #2015).
46. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, and others. 2001. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111-121.
47. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, and others. 2002. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690.
48. Goldstein JA. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
49. Goldstein JA, de Morais SM. 1994. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
50. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelhoin HV, Hardwick JP, Meyer UA. 1988. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446.
51. Guillemette C. 2003. Pharmacogenomics of human UDP- glucuronosyltransferase enzymes. Pharmacogenomics J 3:136-158.
52. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD. 1996. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52-59.
53. Harris BE, Song R, Soong SJ, Diasio RB. 1990. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201.
54. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. 1987. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206.
55. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. 2003. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
56. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, Mizugaki M. 2002. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417-421.
57. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. 2000. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258.
58. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, and others. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the United States of America 97:3473-3478.
59. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. 2001. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273.
60. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, and others. 2001a. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
61. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, and others. 2001b. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454-1459.
62. Ieiri I, Tainaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, and others. 2000. Catalytic activity of three variants (He, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 22:237-244.
63. Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y. 2002. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 47:285-310.
64. Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, Yamane M, Fukumaki Y, Ninomiya H, Tashiro N, and others. 2000. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10:85-89.
65. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. 2002. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616.
66. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, and others. 2004. Genetic variants in the UDP-glucuronosyltransferase IAI gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388.
67. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. 1998. Genetic predisposition to the metabolism of irinotecan (CPT-II). Role of uridine diphosphate glucuronosyltransferase isoform IAI in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854.
68. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, Ratain MJ. 1999. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582.
69. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky HL, Ratain MJ. 2002. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47.
70. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. 1993. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 90:11825-11829.
71. Johnson MR, Van J, Shao L, Albin N, Diasio RB. 1997. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696:183-191.
72. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, and others. 2002. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99:15649-15654.
73. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J. 2002. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805-2811.
74. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. 2002. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 20:3122-3129.
75. Kerb R, Hoffmeyer S, Brinkmann U. 2001. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2:51-64.
76. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. 2001. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803-808.
77. Kim RB. 2003. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33(suppl 2):1-5.
78. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, and others. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
79. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. 2002. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 62:1-6.
80. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J. 2003. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
81. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz E, Pui CH, and others. 2004. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67-72.
82. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, and others. 2002. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
83. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, and others. 2003. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494.
84. Krynetski E, Evans WE. 2003. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22:7403-7413.
85. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, and others. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
86. Kuhara T, Ohdoi C, Ohse M, van Kuilenburg AB, van Gennip AH, Sumi S, Ito T, Wada Y, Matsumoto I. 2003. Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci 792:107-115.
87. Lamba JK, Lin YS, Schuetz EG, Thummel KE. 2002. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
88. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, and others. 2003. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922
89. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. 2001. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
90. Lepper ER, Nooter K, Verweij J, Figg WD, Sparreboom A. 2004. Pharmacogenetics of the ABC transporters ABCB1 and ABCG2. Investig New Drugs (in press).
91. Lockhart AC, Tirona RG, Kim RB. 2003. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2:685-698.
92. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. 1977. Polymorphic hydroxylation of Debrisoquine in man. Lancet 2:584-586.
93. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
94. Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR, Van Gennip AH, De Vries EG. 2002. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86:1028-1033.
95. Marsh S, McLeod HL. 2004. Cancer pharmacogenetics. Br J Cancer 90:8-11.
96. Marzolini C, Pans E, Buclin T, Kim RB. 2004a. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33.
97. Marzolini C, Tirona KG, Kim RB. 2004b. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5:273-282.
98. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. 2001. Clinical pharmacokinetics and metabolism of irinotecan (CPT-II). Clin Cancer Res 7:2182-2194.
99. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. 2002. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94:1247-1249.
100. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. 2003. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253.
101. Mathijssen RH, De Jong FA, Van Schaik RH, Lepper ER, Friberg L, Rietveld T, De Bruijn P, Figg WD, Verweij J, Sparreboom A. 2004. Prediction of irinotecan pharmacokinetics using cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst (in press).
102. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. 2004. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10:2652-2658.
103. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. 1997. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7:187-191.
104. McLeod HL, Siva C. 2002. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3:89-98.
105. McLeod HL, Miller DR, Evans WE. 1993. Azathioprine-indneed myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341:1151.
106. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, and others. 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13.
107. Mizuarai S, Aozasa N, Kotani H. 2004. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246.
108. Morisaki K, Robey RW, Nadjem T, Ozvegy CL, Honjo Y, Huff L, Sparreboom A, Sarkadi B, Bates SE. 2004. The Q141K single-nucleotide polymorphism impacts the transporter activity of ABCG2 [abstract]. Proc Am Assoc Cancer Res 45:2463.
109. Murray GI, Pritchard S, Melvin WT, Burke MD. 1995. Cytochrome P450 CYP3A5 in the human anterior pituitary gland. FEBS Lett 364:79-82.
110. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. 2003. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74:380-387.
111. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. 2000. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
112. Paoluzzi L, Singh A, Price DK, Danesi B, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. 2004. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44:854-860.
113. Puisset F, Chatelut E, Dalene F, Busi F, Cresteil T, Azema J, Ponblanc M, Hennebelle I, Lafont T, Chevreau C, and others. 2004. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 54:265-272.
114. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. 1998. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229.
115. Relling MV, Evans WE, Fonne-Pfister R, Meyer UA. 1989. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res 49:68-71.
116. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. 1999. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008.
117. Sachse C, Brockmoller J, Bauer S, Boots I. 1997. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295.
118. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa B, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, and others. 2003. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13:741-757.
119. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Veruillet L, Risse ML, Boige V, Gouyette A, and others. 2000. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012-2020.
120. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. 2000. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56.
121. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
122. Schmidt B, Baumann F, Hanschmann H, Geissler E, Preiss R. 2001. Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 26:193-200.
123. Schuetz EG. 2004. Lessons from the CYP3A4 promoter. Mol Pharmacol 65:279-281.
124. Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, and others. 2004. PharmGKB Update: II. CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5. Pharmacol Rev 56:159.
125. Schutz E, Gummert J, Mohr E, Oellerich M. 1993. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341:436.
126. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML. 1999. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 147:300-305.
127. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
128. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. 1998. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401.
129. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. 1988. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240-5243.
130. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. 2003. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 6:71-84.
131. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. 2004a. Diflomotecan pharmacokinetics in relation to ABCG2 421C> A genotype. Clin Pharmacol Ther 76:38-44.
132. Sparreboom A, Marsh S, Mathijssen RH, Verweij J, McLeod HL. 2004b. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Investig New Drugs 22:285-289.
133. Spurdle AB, Goodwill B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chenevix-Trench G, Liddle C. 2002. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12:355-366.
134. Stevenson JP, Redlinger M, Klnijtmans LA, Sun W, Algazy K, Giantonio B, Haller DC, Hardy C, Whitehead AS, O'Dwyer PJ. 2001 Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol 19:4081-4087.
135. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. 1996. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
136. Suzuki H, Sugiyama Y. 2002. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 54:1311-1331.
137. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. 1999. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 57:935-939.
138. Thummel KE. 2003. Does the CYP3A5*3 polymorphism affect in vivo drug elimination? Pharmacogenetics 13:585-587.
139. Thummel KE, Wilkinson CR. 1998. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
140. Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
141. Ulrich CM, Robien K, McLeod HL. 2003. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3:912-920.
142. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, Schinkel AH. 2003. The breast cancer resistance protein (Bcrp1/Abeg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. Cancer Res 63:6447-6452.
143. Van Kuilenburg AB. 2004. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939-950.
144. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH. 2001. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:1149-1153.
145. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. 2002a. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12:555-558.
146. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. 2002b. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101:253-258.
147. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. 2001. The CYP3A4*3 allele: is it really-rare? Clin Chem 47:1104-1106.
148. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. 2002. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671.
149. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, Rebbeck TR. 1998. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and
150. Weinshilboum R. 2003. Inheritance and drug response. N Engl J Med 348:529-537.
151. Weinshilboum RM, Sladek SL. 1980. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662.
152. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. 1999. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-205.
153. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. 2003. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
154. Xie HG, Prasad HC, Kim RB, Stein CM. 2002. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257-1270.
155. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. 2004. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
156. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. 2003. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3:53-61.
157. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. 2000. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18:2301-2308.
158. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. 2003. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19-28.
159. Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, and others. 2003. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anticancer Drugs 14:125-135.
160. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, and others. 2001. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-572.